Therapeutic approaches in myelofibrosis and myelodysplastic/myeloproliferative overlap syndromes

OncoTargets and Therapy

Volumn 9, Issue , 2016, Pages 2273-2286

  Sochacki, Andrew L ^a   Fischer, Melissa A ^a   Savona, Michael R ^a,b  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b VANDERBILT INGRAM CANCER CENTER   (United States)

Author keywords

Emerging therapy; MDS MPN neoplasms

Indexed keywords

ALPHA INTERFERON; ANDROGEN; DNA METHYLTRANSFERASE; FEDRATINIB; HYDROXYUREA; IMETELSTAT; INCB 039110; INCB 052793; JANUS KINASE; JANUS KINASE 2; JANUS KINASE INHIBITOR; LENALIDOMIDE; MOMELOTINIB; PACRITINIB; PANOBINOSTAT; PATIDEGIB; PHOSPHATIDYLINOSITOL 3 KINASE; PLACEBO; PROTEIN KINASE B; RUXOLITINIB; SIMTUZUMAB; SONIC HEDGEHOG PROTEIN; SONIDEGIB; STAT PROTEIN; TELOMERASE; THALIDOMIDE; UNCLASSIFIED DRUG;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; CALR GENE; DRUG WITHDRAWAL; ENZYME INHIBITION; EPIGENETICS; G1 PHASE CELL CYCLE CHECKPOINT; GENE; HUMAN; IMMUNOTHERAPY; INTERNATIONAL PROGNOSTIC SCORING SYSTEM; JAK2 GENE; MIXED MYELODYSPLASTIC MYELOPROLIFERATIVE DISEASE; MOLECULAR PATHOLOGY; MYELOFIBROSIS; OUTCOME ASSESSMENT; REVIEW; SIGNAL TRANSDUCTION; SPLENECTOMY; SPLENOMEGALY; THROMBOCYTOPENIA;

EID: 84964561151     PISSN: None     EISSN: 11786930     Source Type: Journal    
DOI: 10.2147/OTT.S83868     Document Type: Review

References (162)

1. Ma Z, DeBusk L, Chandra P, et al. Array-Based Comparative Genomic Hybridization (aCGH) In Myelofibrosis Reveals Divergent Genetic Copy Number Alterations Among Patients With Post-Essential Thrombocythemia-Myelofibrosis/Post-Polycythemia Rubra Vera-Myelofibrosis (PET-MF and PPV-MF) and Pat. Blood. 2013;122(21):5266.
2. Tefferi A, Thiele J, Orazi A, et al. Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recom-mendations from an ad hoc international expert panel. Blood. 2007; 110(4):1092-1097.
3. Cervantes F, Dupriez B, Pereira A, et al. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood. 2009;113(13):2895-2901.
4. Passamonti F, Cervantes F, Vannucchi AM, et al. Dynamic International Prognostic Scoring System (DIPSS) predicts progression to acute myeloid leukemia in primary myelofibrosis. Blood. 2010; 116(15):2857-2858.
5. Padron E, Garcia-Manero G, Patnaik MM, et al. An international data set for CMML validates prognostic scoring systems and demonstrates a need for novel prognostication strategies. Blood Cancer J. 2015; 5:e333.
6. Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114(5):937-951.
7. Niemeyer CM, Kratz CP. Paediatric myelodysplastic syndromes and juvenile myelomonocytic leukaemia: molecular classification and treatment options. Br J Haematol. 2008;140(6):610-624.
8. Tartaglia M, Mehler EL, Goldberg R, et al. Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome. Nat Genet. 2001;29(4):465-468.
9. Foucar K. Myelodysplastic/myeloproliferative neoplasms. Am J Clin Pathol. 2009;132(2):281-289.
10. Itzykson R, Kosmider O, Renneville A, et al. Prognostic score including gene mutations in chronic myelomonocytic leukemia. J Clin Oncol. 2013;31(19):2428-2436.
11. Savona MR, Malcovati L, Komrokji R, et al. An international consortium proposal of uniform response criteria for myelodysplastic/ myeloproliferative neoplasms (MDS/MPN) in adults. Blood. 2015; 125(12):1857-1865.
12. Martínez-Trillos A, Gaya A, Maffioli M, et al. Efficacy and tolerability of hydroxyurea in the treatment of the hyperproliferative manifestations of myelofibrosis: results in 40 patients. Ann Hematol. 2010; 89(12):1233-1237.
13. Hanft VN, Fruchtman SR, Pickens CV, Rosse WF, Howard TA, Ware RE. Acquired DNA mutations associated with in vivo hydroxyurea exposure. Blood. 2000;95(11):3589-3593.
14. Sirhan S, Lasho TL, Hanson CA, Mesa RA, Pardanani A, Tefferi A. The presence of JAK2V617F in primary myelofibrosis or its allele burden in polycythemia vera predicts chemosensitivity to hydroxyurea. Am J Hematol. 2008;83(5):363-365.
15. Mesa RA, Nagorney DS, Schwager S, Allred J, Tefferi A. Palliative goals, patient selection, and perioperative platelet management: outcomes and lessons from 3 decades of splenectomy for myelofibrosis with myeloid metaplasia at the Mayo Clinic. Cancer. 2006; 107(2):361-370.
16. Santos FP, Tam CS, Kantarjian H, et al. Splenectomy in patients with myeloproliferative neoplasms: efficacy, complications and impact on survival and transformation. Leuk Lymphoma. 2014;55(1):121-127.
17. Somasundaram SK, Massey L, Gooch D, Reed J, Menzies D. Laparo- scopic splenectomy is emerging ‘gold standard’ treatment even for massive spleens. Ann R Coll Surg Engl. 2015;97(5):345-348.
18. Deeg HJ, Gooley TA, Flowers ME, et al. Allogeneic hematopoietic stem cell transplantation for myelofibrosis. Blood. 2003;102(12): 3912-3918.
19. Kroger N, Giorgino T, Scott BL, et al. Impact of allogeneic stem cell transplantation on survival of patients less than 65 years of age with primary myelofibrosis. Blood. 2015;125(21):3347-3350; quiz 3364.
20. Cervantes F, Barosi G, Demory JL, et al. Myelofibrosis with myeloid metaplasia in young individuals: disease characteristics, prognostic factors and identification of risk groups. Br J Haematol. 1998;102(3):684-690.
21. Mesa RA, Li CY, Ketterling RP, Schroeder GS, Knudson RA, Tefferi A. Leukemic transformation in myelofibrosis with myeloid metaplasia: a single-institution experience with 91 cases. Blood. 2005;105(3):973-977.
22. Patel KP, Newberry KJ, Luthra R, et al. Correlation of mutation profile and response in patients with myelofibrosis treated with ruxolitinib. Blood. 2015;126(6):790-797.
23. Gupta V, Hari P, Hoffman R. Allogeneic hematopoietic cell trans- plantation for myelofibrosis in the era of JAK inhibitors. Blood. 2012; 120(7):1367-1379.
24. Robin M, Tabrizi R, Mohty M, et al. Allogeneic haematopoietic stem cell transplantation for myelofibrosis: a report of the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC). Br J Haematol. 2011;152(3):331-339.
25. Bregante S, Dominietto A, Ghiso A, et al. Improved outcome of alternative donor transplantations in patients with myelofibrosis: from unrelated to haploidentical family donors. Biol Blood Marrow Transplant. 2016;22(2):324-329.
26. Francois S, Huynh A, Cassinat B, et al. Ruxolitinib before allogeneic hematopoietic stem cell transplantation (HSCT) in patients with myelofibrosis: a preliminary descriptive report of the JAK ALLO study, a phase II trial sponsored by Goelams-FIM in collaboration with the SFGMTC. Blood. 2013;122(21):306.
27. Jaekel N, Behre G, Behning A, et al. Allogeneic hematopoietic cell transplantation for myelofibrosis in patients pretreated with the JAK1 and JAK2 inhibitor ruxolitinib. Bone Marrow Transplant. 2014;49(2): 179-184.
28. Stübig T, Alchalby H, Ditschkowski M, et al. JAK inhibition with ruxolitinib as pretreatment for allogeneic stem cell transplantation in primary or post-ET/PV myelofibrosis. Leukemia. 2014;28(8):1736-1738.
29. Rubio MT, Legrand F, Kiladjian J-J, et al. Ruxolitinib for patients with primary or secondary myelofibrosis before allogeneic hematopoietic stem cell transplantation (allo-HSCT): a retrospective study of the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC). Blood. 2013;122(21):2111.
30. Mughal TI, Cross NC, Padron E, et al. An International MDS/MPN working group’s perspective and recommendations on molecular pathogenesis, diagnosis and clinical characterization of myelo-dysplastic/myeloproliferative neoplasms. Haematologica. 2015; 100(9):1117-1130.
31. Brubaker LH, Brière J, Laszlo J, et al. Treatment of anemia in myeloproliferative disorders: a randomized study of fluoxymesterone v transfusions only. Arch Intern Med. 1982;142(8):1533-1537.
32. Cervantes F, Alvarez-Larrán A, Domingo A, Arellano-Rodrigo E, Montserrat E. Efficacy and tolerability of danazol as a treatment for the anaemia of myelofibrosis with myeloid metaplasia: long-term results in 30 patients. Br J Haematol. 2005;129(6):771-775.
33. Tefferi A, Elliot MA, Yoon SY, et al. Clinical and bone marrow effects of interferon alfa therapy in myelofibrosis with myeloid metaplasia. Blood. 2001;97(6):1896.
34. Silver RT, Feldman EJ, Ritchie E, et al. Recombinant interferon alpha (rIFN) may retard progression of early myelofibrosis by reducing splenomegaly and by decreasing marrow fibrosis. Blood. 2013;122(21):4053.
35. Thomas DA, Giles FJ, Albitar M, et al. Thalidomide therapy for myelo-fibrosis with myeloid metaplasia. Cancer. 2006;106(9):1974-1984.
36. Mesa RA, Steensma DP, Pardanani A, et al. A phase 2 trial of combination low-dose thalidomide and prednisone for the treatment of myelo-fibrosis with myeloid metaplasia. Blood. 2003;101(7):2534-2541.
37. Mesa RA, Yao X, Cripe LD, et al. Lenalidomide and prednisone for myelofibrosis: Eastern Cooperative Oncology Group (ECOG) phase 2 trial E4903. Blood. 2010;116(22):4436-4438.
38. Quintás-Cardama A, Kantarjian HM, Manshouri T, et al. Lenalidomide plus prednisone results in durable clinical, histopathologic, and molecular responses in patients with myelofibrosis. J Clin Oncol. 2009; 27(28):4760-4766.
39. Thapaliya P, Tefferi A, Pardanani A, et al. International working group for myelofibrosis research and treatment response assessment and long‐term follow-up of 50 myelofibrosis patients treated with thalidomideprednisone based regimens. Am J Hematol. 2011;86(1):96-98.
40. Begna KH, Pardanani A, Mesa R, et al. Long-term outcome of pomali-domide therapy in myelofibrosis. Am J Hematol. 2012;87(1):66-68.
41. Daver N, Cortes J, Newberry K, et al. Ruxolitinib in combination with lenalidomide as therapy for patients with myelofibrosis. Haematologica. 2015;100(8):1058-1063.
42. Vainchenker W, Constantinescu SN. A unique activating mutation in JAK2 (V617F) is at the origin of polycythemia vera and allows a new classification of myeloproliferative diseases. Hematology Am Soc Hematol Educ Program. 2005:195-200.
43. Baker SJ, Rane SG, Reddy EP. Hematopoietic cytokine receptor signaling. Oncogene. 2007;26(47):6724-6737.
44. Nosaka T, van Deursen JM, Tripp RA, et al. Defective lymphoid development in mice lacking Jak3. Science. 1995;270(5237):800-802.
45. Vainchenker W, Dusa A, Constantinescu SN. JAKs in pathology: role of Janus kinases in hematopoietic malignancies and immunodeficiencies. Semin Cell Dev Biol. 2008;19(4):385-393.
46. James C, Ugo V, Le Couédic JP, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature. 2005;434(7037):1144-1148.
47. Kralovics R, Teo SS, Buser AS, et al. Altered gene expression in myeloproliferative disorders correlates with activation of signaling by the V617F mutation of Jak2. Blood. 2005;106(10):3374-3376.
48. Lu X, Levine R, Tong W, et al. Expression of a homodimeric type I cytokine receptor is required for JAK2V617F-mediated transformation. Proc Natl Acad Sci U S A. 2005;102(52):18962-18967.
49. Steensma DP, Dewald GW, Lasho TL, et al. The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both “atypical” myeloproliferative disorders and myelodysplastic syndromes. Blood. 2005;106(4):1207-1209.
50. Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 2005;7(4): 387-397.
51. Beer PA, Campbell PJ, Scott LM, et al. MPL mutations in myelopro-liferative disorders: analysis of the PT-1 cohort. Blood. 2008;112(1): 141-149.
52. Nangalia J, Massie CE, Baxter EJ, et al. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med. 2013;369(25):2391-2405.
53. Klampfl T, Gisslinger H, Harutyunyan AS, et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med. 2013; 369(25):2379-2390.
54. Tefferi A, Lasho T, Finke C, et al. Type 1 vs type 2 calreticulin mutations in primary myelofibrosis: differences in phenotype and prognostic impact. Leukemia. 2014;28(7):1568-1570.
55. Tefferi A, Lasho TL, Tischer A, et al. The prognostic advantage of calreticulin mutations in myelofibrosis might be confined to type 1 or type 1-like CALR variants. Blood. 2014;124(15):2465-2466.
56. Tefferi A, Guglielmelli P, Lasho TL, et al. CALR and ASXL1 mutations-based molecular prognostication in primary myelofibrosis: an international study of 570 patients. Leukemia. 2014;28(7):1494-1500.
57. Ortmann CA, Kent DG, Nangalia J, et al. Effect of mutation order on myeloproliferative neoplasms. N Engl J Med. 2015;372(7): 601-612.
58. Meggendorfer M, Roller A, Haferlach T, et al. SRSF2 mutations in 275 cases with chronic myelomonocytic leukemia (CMML). Blood. 2012;120(15): 3080-3088.
59. Broseus J, Alpermann T, Wulfert M, et al. Age, JAK2V617F and SF3B1 mutations are the main predicting factors for survival in refractory anaemia with ring sideroblasts and marked thrombocytosis. Leukemia. 2013;27(9):1826-1831.
60. Verstovsek S, Mesa RA, Gotlib J, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med. 2012; 366(9):799-807.
61. Harrison C, Kiladjian JJ, Al-Ali HK, et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med. 2012; 366(9):787-798.
62. Quintás-Cardama A, Vaddi K, Liu P, et al. Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms. Blood. 2010;115(15):3109-3117.
63. Verstovsek S, Kantarjian H, Mesa RA, et al. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med. 2010;363(12):1117-1127.
64. Tefferi A, Pardanani A. Serious adverse events during ruxolitinib treat- ment discontinuation in patients with myelofibrosis. Mayo Clin Proc. 2011;86(12):1188-1191.
65. Padron E, Dezern AE, Vaddi K, et al. A multi-institution phase I trial of ruxolitinib in chronic myelomonocytic leukemia (CMML). Clin Cancer Res. Epub 2016 Feb 8.
66. Desterke C, Bilhou-Nabera C, Guerton B, et al. FLT3-mediated p38-MAPK activation participates in the control of megakaryopoiesis in primary myelofibrosis. Cancer Res. 2011;71(8):2901-2915.
67. Kiyoi H. Flt3 inhibitors: recent advances and problems for clinical application. Nagoya J Med Sci. 2015;77(1-2):7-17.
68. Zhang W, Konopleva M, Shi YX, et al. Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia. J Natl Cancer Inst. 2008; 100(3):184-198.
69. Ravandi F, Cortes JE, Jones D, et al. Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia. J Clin Oncol. 2010;28(11):1856-1862.
70. Tallman MS, Schiller G, Trone D, et al. Results of a phase 2 randomized, open-label, study of lower doses of quizartinib (AC220;ASP2689) in subjects with FLT3-ITD positive relapsed or refractory acute myeloid leukemia (AML). Blood. 2013;122(21):494.
71. Stone R, Mandrekar S, Sanford B. The multi-kinase inhibitor midostaurin prolongs survival compared with placebo in combination with daunorubicin/cytarabine induction, high-dose consolidation, and as maintenance therapy in newly diagnosed acute myeloid leukemia patients age 18-60 with FLT3 mutations: an international prospective randomized placebo-controlled double-blind trial (CALGB 10603/ RATIFY [Alliance]). Poster presented at: 57th ASH Annual Meeting and Exposition; December 5-8, 2015; Orlando, FL.
72. Dean JP, Cernohous P, Komrokji RS, et al. Pacritinib, a dual JAK2/ FLT3 inhibitor: an integrated efficacy and safety analysis of phase II trial data in patients with primary and secondary myelofibrosis (MF) and platelet counts #100,000/µl. Blood. 2013;122(21):395.
73. Komrokji RS, Seymour JF, Roberts AW, et al. Results of a phase 2 study of pacritinib (SB1518), a JAK2/JAK2(V617F) inhibitor, in patients with myelofibrosis. Blood. 2015;125(17):2649-2655.
74. Mesa RA, Egyed M, Szoke A, et al. Results of the PERSIST-1 phase III study of pacritinib (PAC) versus best available therapy (BAT) in primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF), or post-essential thrombocythemia-myelofibrosis (PET-MF). J Clin Oncol. 2015;33 Suppl:LBA7006.
75. Talpaz M, Paquette R, Afrin L, et al. Interim analysis of safety and efficacy of ruxolitinib in patients with myelofibrosis and low platelet counts. J Hematol Oncol. 2013;6(1):81.
76. Tyner JW, Bumm TG, Deininger J, et al. CYT387, a novel JAK2 inhibitor, induces hematologic responses and normalizes inflammatory cytokines in murine myeloproliferative neoplasms. Blood. 2010;115(25):5232-5240.
77. Pardanani A, Laborde RR, Lasho TL, et al. Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis. Leukemia. 2013;27(6):1322-1327.
78. Abdelrahman RA, Begna KH, Al-Kali A, et al. Momelotinib treatment-emergent neuropathy: prevalence, risk factors and outcome in 100 patients with myelofibrosis. Br J Haematol. 2015;169(1): 77-80.
79. Winton EF, Devos T, Oh ST, et al. Phase III randomized, double-blind, active-controlled study of momelotinib versus ruxolitinib in patients with myelofibrosis. J Clin Oncol. 2015;33 Suppl:TPS7101.
80. Gupta V, Baer MR, Oh ST, et al. Phase III randomized, open-label, active-controlled study of momelotinib versus best available therapy in ruxolitinib-treated patients with myelofibrosis. J Clin Oncol. 2015;33 Suppl:TPS7102.
81. Pardanani A, Tefferi A, Jamieson C, et al. A phase 2 randomized doseranging study of the JAK2-selective inhibitor fedratinib (SAR302503) in patients with myelofibrosis. Blood Cancer J. 2015;5:e335.
82. Pardanani A, Gotlib JR, Jamieson C, et al. Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis. J Clin Oncol. 2011;29(7):789-796.
83. Harrison CN, Cortes JE, Cervantes F, et al. Results of a randomized, double-blind, placebo-controlled phase iii study (JAKARTA) of the JAK2-selective inhibitor fedratinib (SAR302503) in patients with myelofibrosis (MF). Blood. 2013;122(21):393.
84. Zhang Q, Zhang Y, Diamond S, et al. The Janus kinase 2 inhibitor fedratinib inhibits thiamine uptake: a putative mechanism for the onset of Wernicke’s encephalopathy. Drug Metab Dispos. 2014; 42(10):1656-1662.
85. Mascarenhas JO, Talpaz M, Gupta V, et al. Primary analysis results from an open-label phase II study of INCB039110, a selective JAK1 inhibitor, in patients with myelofibrosis. Blood. 2014;124(21):714.
86. Low JA, de Sauvage FJ. Clinical experience with Hedgehog pathway inhibitors. J Clin Oncol. 2010;28(36):5321-5326.
87. Irvine DA, Copland M. Targeting hedgehog in hematologic malignancy. Blood. 2012;119(10):2196-2204.
88. Greenbaum LE. Hedgehog signaling in biliary fibrosis. J Clin Invest. 2008;118(10):3263-3265.
89. McGowan SE, McCoy DM. Platelet-derived growth factor-A and sonic hedgehog signaling direct lung fibroblast precursors during alveolar septal formation. Am J Physiol Lung Cell Mol Physiol. 2013;305(3):L229-L239.
90. Pasca di Magliano M, Hebrok M. Hedgehog signalling in cancer formation and maintenance. Nat Rev Cancer. 2003;3(12):903-911.
91. Olive KP, Jacobetz MA, Davidson CJ, et al. Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science. 2009;324(5933):1457-1461.
92. Keller MD, Rampal RK, Shank K, et al. Improved efficacy of combination of JAK2 and hedgehog inhibitors in myelofibrosis. Blood. 2013;122(21):666.
93. Jimeno A, Weiss GJ, Miller WH Jr., et al. Phase I study of the Hedge- hog pathway inhibitor IPI-926 in adult patients with solid tumors. Clin Cancer Res. 2013;19(10):2766-2774.
94. Sasaki K, Gotlib JR, Mesa RA, et al. Phase II evaluation of IPI-926, an oral Hedgehog inhibitor, in patients with myelofibrosis. Leuk Lymphoma. 2015;56(7):2092-2097.
95. Martinelli G, Oehler VG, Papayannidis C, et al. Treatment with PF-04449913, an oral smoothened antagonist, in patients with myeloid malignancies: a phase 1 safety and pharmacokinetics study. Lancet Haematol. 2015;2(8):e339-e346.
96. Gupta V, Koschmieder S, Harrison CN, et al. Phase 1B dose-escalation study of sonidegib (LDE225) in combination with ruxolitinib (INC424) in patients with myelofibrosis. Poster presented at: 56th ASH Annual Meeting and Exposition; December 6-9, 2014; San Francisco, CA.
97. Wang JC, Chen C, Dumlao T, et al. Enhanced histone deacetylase enzyme activity in primary myelofibrosis. Leuk Lymphoma. 2008;49(12):2321-2327.
98. Meadows SA, Nguyen HM, Queva C, et al. PI3Kδ inhibitor idelalisib inhibits AKT signaling in myelofibrosis patients on chronic JAK inhibitor therapy. Blood. 2013;122(21):4065.
99. Burris HA, Patel MR, Lanasa MC, et al. Activity of TGR-1202, a novel once-daily PI3Kδ inhibitor, in patients with relapsed or refractory hematologic malignancies. J Clin Oncol. 2014;32(15 Suppl):2513
100. Gutierrez M, Lanasa M, Deng C, et al. A phase I dose escalation study of TGR-1202, a novel PI3K-δ inhibitor, for patients with relapsed or refractory hematologic malignancies. Blood. 2013;122(21):4373.
101. Nanthakumar CB, Hatley RJ, Lemma S, Gauldie J, Marshall RP, Macdonald SJ. Dissecting fibrosis: therapeutic insights from the small- molecule toolbox. Nat Rev Drug Discov. 2015;14(10):693-720.
102. Verstovsek S, Mesa RA, Foltz LM, et al. Phase 2 trial of PRM-151, an anti-fibrotic agent, in patients with myelofibrosis: stage 1 results. Blood. 2014;124(21):713.
103. Verstovsek S, Savona MR, Mesa RA, et al. A phase 2 study to evaluate the efficacy and safety of simtuzumab in adult subjects with primary, post polycythemia vera (PV) or post essential thrombocythemia (ET) myelofibrosis. Poster presented at: 57th ASH Annual Meeting and Exposition; December 5-8, 2015; Orlando, FL.
104. Tefferi A, Lasho TL, Begna KH, et al. A pilot study of the telom- erase inhibitor imetelstat for myelofibrosis. N Engl J Med. 2015; 373(10):908-919.
105. Mascarenhas J, Lu M, Li T, et al. A phase I study of panobinostat (LBH589) in patients with primary myelofibrosis (PMF) and post-polycythaemia vera/essential thrombocythaemia myelofibrosis (post-PV/ET MF). Br J Haematol. 2013;161(1):68-75.
106. DeAngelo DJ, Mesa RA, Fiskus W, et al. Phase II trial of panobinostat, an oral pan-deacetylase inhibitor in patients with primary myelofibro-sis, post-essential thrombocythaemia, and post-polycythaemia vera myelofibrosis. Br J Haematol. 2013;162(3):326-335.
107. Kiladjian JJ, Heidel FH, Vannucchi AM, et al. Efficacy, safety, and confirmation of the recommended phase 2 dose of ruxolitinib plus panobinostat in patients with intermediate or high-risk myelofibrosis. Blood. 2014;124(21):711.
108. Andersen CL, Mortensen NB, Klausen TW, Vestergaard H, Bjerrum OW, Hasselbalch HC. A phase II study of vorinostat (MK-0683) in patients with primary myelofibrosis and post-polycythemia vera myelofibrosis. Haematologica. 2014;99(1):e5-e7.
109. Nischal S, Bhattacharyya S, Christopeit M, et al. Methylome profiling reveals distinct alterations in phenotypic and mutational sub-groups of myeloproliferative neoplasms. Cancer Res. 2013;73(3): 1076-1085.
110. Quintas-Cardama A, Tong W, Kantarjian H, et al. A phase II study of 5-azacitidine for patients with primary and post-essential throm-bocythemia/polycythemia vera myelofibrosis. Leukemia. 2008; 22(5):965-970.
111. Wolfromm A, Dreyfus F, Vey N, et al. Treatment of advanced CMML by azacitidine (AZA) in a compassionate program: the GFM experience in 38 patients (pts). Poster presented at: 53rd ASH Annual Meeting and Exposition; December 10-13, 2011; San Diego, CA
112. Odenike OM, Godwin JE, Van Besien K, et al. Phase II trial of low dose, subcutaneous decitabine in myelofibrosis. Poster presented at: 50th ASH Annual Meeting and Exposition; December 6-9, 2008; San Francisco, CA.
113. Harel S, Cherait A, Berthon C, et al. Outcome of patients with high risk myelodysplastic syndrome (MDS) and advanced chronic myelo-monocytic leukemia (CMML) treated with decitabine after azacitidine failure. Leuk Res. 2015;39(5):501-504.
114. Warfel NA, Kraft AS. PIM kinase (and Akt) biology and signaling in tumors. Pharmacol Ther. 2015;151:41-49.
115. Mahadevan D, Shirahatti N. Strategies for targeting the multidrug resistance-1 (MDR1)/P-gp transporter in human malignancies. Curr Cancer Drug Targets. 2005;5(6):445-455.
116. Keane N, Reidy M, Natoni A, Raab M, O’Dwyer M. Targeting the Pim kinases in multiple myeloma. Blood Cancer J. 2015;5(7):e325
117. Koblish H, Shin N, Hall L, et al. Activity of the pan-PIM kinase inhibitor INCB053914 in models of acute myelogenous leukemia. Cancer Res. 2015;75(15 Suppl):5416.
118. Radin AI, Kim HT, Grant BW, et al. Phase II study of α2 interferon in the treatment of the chronic myeloproliferative disorders (E5487): a trial of the Eastern Cooperative Oncology Group. Cancer. 2003;98(1):100-109
119. Shin N, Covington M, Wynn R, et al. Characterization of INCB053914, a novel pan-PIM kinase inhibitor. Cancer Res. 2015;75(15 Suppl):5397.
120. Swords RT, Erba HP, DeAngelo DJ, et al. Pevonedistat (MLN4924), a first-in-class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukaemia and myelodysplastic syndromes: a phase 1 study. Br J Haematol. 2015;169(4):534-543.
121. Swords RT, Savona MR, Maris MB, et al. Pevonedistat (MLN4924), an Investigational, first-in-class NAE inhibitor, in combination with azacitidine in elderly patients with acute myeloid leukemia (AML) considered unfit for conventional chemotherapy: updated results from the phase 1 C15009 trial. Blood. 2014;124(21):2313.
122. Kröger N, Holler E, Kobbe G, et al. Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Blood. 2009;114(26):5264-5270.
123. Libutti S. Genetically engineered lymphocytes and adoptive cell therapy: cancer immunotherapy’s smart bombs. Cancer Gene Ther. 2015;22(2):63.
124. Armand P. Immune checkpoint blockade in hematologic malignancies. Blood. 2015;125(22):3393-3400.
125. Hodi FS, O’Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711-723.
126. Smith BD, Kasamon YL, Kowalski J, et al. K562/GM-CSF immunotherapy reduces tumor burden in chronic myeloid leukemia patients with residual disease on imatinib mesylate. Clin Cancer Res. 2010;16(1):338-347.
127. Bachireddy P, Burkhardt UE, Rajasagi M, Wu CJ. Haematological malignancies: at the forefront of immunotherapeutic innovation. Nat Rev Cancer. 2015;15(4):201-215.
128. Ho VT, Vanneman M, Kim H, et al. Biologic activity of irradiated, autologous, GM-CSF-secreting leukemia cell vaccines early after allogeneic stem cell transplantation. Proc Natl Acad Sci U S A. 2009; 106(37):15825-15830.
129. Cazzola M, Kralovics R. From Janus kinase 2 to calreticulin: the clinically relevant genomic landscape of myeloproliferative neoplasms. Blood. 2014;123(24):3714-3719.
130. Abdel-Wahab O, Levine RL. Genetics of the myeloproliferative neoplasms. In: Verstovsek S, Tefferi A, editors. Myeloproliferative Neoplasms. Heidelberg: Springer; 2011:39-68.
131. Rumi E, Pietra D, Pascutto C, et al. Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis. Blood. 2014; 124(7):1062-1069.
132. Vannucchi AM, Lasho TL, Guglielmelli P, et al. Mutations and prog- nosis in primary myelofibrosis. Leukemia. 2013;27(9):1861-1869
133. Chang TY, Dvorak CC, Loh ML. Bedside to bench in juvenile myelomonocytic leukemia: insights into leukemogenesis from a rare pediatric leukemia. Blood. 2014;124(16):2487-2497.
134. Kim E, Abdel-Wahab O. Focus on the epigenome in the myeloproliferative neoplasms. Hematology Am Soc Hematol Educ Program. 2013; 2013:538-544.
135. Stegelmann F, Bullinger L, Schlenk R, et al. DNMT3A mutations in myeloproliferative neoplasms. Leukemia. 2011;25(7):1217-1219
136. Laborde R, Patnaik M, Lasho T, et al. SETBP1 mutations in 415 patients with primary myelofibrosis or chronic myelomonocytic leukemia: independent prognostic impact in CMML. Leukemia. 2013; 27(10):2100-2102.
137. Piazza R, Valletta S, Winkelmann N, et al. Recurrent SETBP1 mutations in atypical chronic myeloid leukemia. Nat Genet. 2013;45(1): 18-24.
138. Greaves WO, Verma S, Bisrat T, et al. TP53 mutation is rare in primary myelofibrosis. Leuk Lymphoma. 2013;54(7):1552.
139. Raza S, Viswanatha D, Frederick L, et al. TP53 mutations and polymorphisms in primary myelofibrosis. Am J Hematol. 2012;87(2): 204-206.
140. Passamonti F, Maffioli M, Caramazza D, Cazzola M. Myeloproliferative neoplasms: from JAK2 mutations discovery to JAK2 inhibitor therapies. Oncotarget. 2011;2(6):485-490.
141. Soriano G, Heaney M. Polycythemia vera and essential thrombocythemia: new developments in biology with therapeutic implications. Curr Opin Hematol. 2013;20(2):169-175.
142. Tefferi A, Vainchenker W. Myeloproliferative neoplasms: molecular pathophysiology, essential clinical understanding, and treatment strategies. J Clin Oncol. 2011;29(5):573-582.
143. Such E, Germing U, Malcovati L, et al. Development and validation of a prognostic scoring system for patients with chronic myelomonocytic leukemia. Blood. 2013;121(15):3005-3015.
144. Jankowska AM, Makishima H, Tiu RV, et al. Mutational spectrum analysis of chronic myelomonocytic leukemia includes genes associated with epigenetic regulation: UTX, EZH2, and DNMT3A. Blood. 2011;118(14):3932-3941.
145. Makishima H, Yoshida K, Nguyen N, et al. Somatic SETBP1 mutations in myeloid malignancies. Nat Genet. 2013;45(8):942-946.
146. Patnaik M, Padron E, LaBorde R, et al. Mayo prognostic model for WHO-defined chronic myelomonocytic leukemia: ASXL1 and spliceosome component mutations and outcomes. Leukemia. 2013; 27(7):1504-1510.
147. Score J, Hidalgo-Curtis C, Jones AV, et al. Inactivation of poly- comb repressive complex 2 components in myeloproliferative and myelodysplastic/myeloproliferative neoplasms. Blood. 2012;119(5): 1208-1213.
148. Jankowska AM, Szpurka H, Tiu RV, et al. Loss of heterozygosity 4q24 and TET2 mutations associated with myelodysplastic/myeloproliferative neoplasms. Blood. 2009;113(25):6403-6410
149. Kar SA, Jankowska A, Makishima H, et al. Spliceosomal gene mutations are frequent events in the diverse mutational spectrum of chronic myelomonocytic leukemia but largely absent in juvenile myelomono- cytic leukemia. Haematologica. 2013;98(1):107-113.
150. Loh ML, Sakai DS, Flotho C, et al. Mutations in CBL occur frequently in juvenile myelomonocytic leukemia. Blood. 2009;114(9): 1859-1863.
151. Muramatsu H, Makishima H, Jankowska AM, et al. Mutations of an E3 ubiquitin ligase c-Cbl but not TET2 mutations are pathogenic in juvenile myelomonocytic leukemia. Blood. 2010;115(10):1969-1975
152. Sakaguchi H, Okuno Y, Muramatsu H, et al. Exome sequencing identifies secondary mutations of SETBP1 and JAK3 in juvenile myelomonocytic leukemia. Nat Genet. 2013;45(8):937-941.
153. Sugimoto Y, Muramatsu H, Makishima H, et al. Spectrum of molecular defects in juvenile myelomonocytic leukaemia includes ASXL1 mutations. Br J Haematol. 2010;150(1):83-87.
154. Visconte V, Makishima H, Jankowska A, et al. SF3B1, a splicing factor is frequently mutated in refractory anemia with ring sideroblasts. Leukemia. 2012;26(3):542-545.
155. Eder C, Weissmann S, Meggendorfer M, et al. RARS-T patients harbor SF3B1 mutations in 90.2% and can be characterized by mutations in ASXL1 and other spliceosome genes in most of the remaining cases. Blood. 2013;122(21):2764.
156. Szpurka H, Jankowska AM, Makishima H, et al. Spectrum of mutations in RARS-T patients includes TET2 and ASXL1 mutations. Leuk Res. 2010;34(8):969-973.
157. Szpurka H, Tiu R, Murugesan G, et al. Refractory anemia with ringed sideroblasts associated with marked thrombocytosis (RARS-T), another myeloproliferative condition characterized by JAK2 V617F mutation. Blood. 2006;108(7):2173-2181.
158. Tiu RV, Gondek LP, O’Keefe CL, et al. Prognostic impact of SNP array karyotyping in myelodysplastic syndromes and related myeloid malignancies. Blood. 2011;117(17):4552-4560.
159. Gotlib J, Maxson JE, George TI, Tyner JW. The new genetics of chronic neutrophilic leukemia and atypical CML: implications for diagnosis and treatment. Blood. 2013;122(10):1707-1711.
160. Makishima H, Jankowska A, Tiu R, et al. Novel homo-and hemizygous mutations in EZH2 in myeloid malignancies. Leukemia. 2010;24(10):1799-1804.
161. Liu Y, Tabarroki A, Visconte V, et al. A prognostic scoring system for unclassifiable MDS and MDS/MPN. Poster presented at: 54th ASH Annual Meeting and Exposition; December 8-11, 2012; Atlanta, GA
162. Ernst T, Chase AJ, Score J, et al. Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders. Nat Genet. 2010; 42(8):722-726.